S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
New CBOE “special perk” helps traders target income every weekend (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts

Arrowhead Pharmaceuticals (ARWR) Competitors

$23.17
+1.97 (+9.29%)
(As of 12/1/2023 ET)
Compare
Today's Range
$20.67
▼
$23.24
50-Day Range
$21.20
▼
$29.12
52-Week Range
$20.67
▼
$42.48
Volume
4.22 million shs
Average Volume
1.16 million shs
Market Capitalization
$2.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.00
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

ARWR vs. AXSM, CYTK, RARE, OGN, PBH, HCM, INSM, ZLAB, EVO, and NUVL

Should you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Ultragenyx Pharmaceutical (RARE), Organon & Co. (OGN), Prestige Consumer Healthcare (PBH), HUTCHMED (HCM), Insmed (INSM), Zai Lab (ZLAB), Evotec (EVO), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical preparations" industry.

Arrowhead Pharmaceuticals vs.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.

Arrowhead Pharmaceuticals has a net margin of -85.27% compared to Axsome Therapeutics' net margin of -90.33%. Arrowhead Pharmaceuticals' return on equity of -53.65% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-85.27% -53.65% -24.55%
Axsome Therapeutics -90.33%-88.79%-35.35%

66.0% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.6% of Axsome Therapeutics shares are owned by institutional investors. 5.0% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 24.5% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.

In the previous week, Arrowhead Pharmaceuticals had 17 more articles in the media than Axsome Therapeutics. MarketBeat recorded 19 mentions for Arrowhead Pharmaceuticals and 2 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.15 beat Arrowhead Pharmaceuticals' score of 0.41 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
3 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Axsome Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Arrowhead Pharmaceuticals presently has a consensus target price of $53.00, indicating a potential upside of 128.74%. Axsome Therapeutics has a consensus target price of $105.50, indicating a potential upside of 55.15%. Given Arrowhead Pharmaceuticals' higher probable upside, equities analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.64
Axsome Therapeutics
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Arrowhead Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$240.74M10.34-$176.06M-$1.93-12.01
Axsome Therapeutics$50.04M64.30-$187.13M-$4.53-15.01

Arrowhead Pharmaceuticals received 122 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. However, 67.18% of users gave Axsome Therapeutics an outperform vote while only 65.20% of users gave Arrowhead Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Arrowhead PharmaceuticalsOutperform Votes
517
65.20%
Underperform Votes
276
34.80%
Axsome TherapeuticsOutperform Votes
395
67.18%
Underperform Votes
193
32.82%

Summary

Arrowhead Pharmaceuticals beats Axsome Therapeutics on 11 of the 18 factors compared between the two stocks.


Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARWR vs. The Competition

Export to Excel
MetricArrowhead PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.49B$5.51B$4.55B$6.74B
Dividend YieldN/A2.95%2.90%4.83%
P/E Ratio-12.019.18108.2012.69
Price / Sales10.34791.232,791.16169.33
Price / CashN/A18.9885.31138.60
Price / Book8.684.345.195.06
Net Income-$176.06M$185.82M$123.42M$177.19M
7 Day Performance-20.43%4.58%2.71%2.67%
1 Month Performance-17.69%4.02%5.31%5.64%
1 Year Performance-31.71%5.59%5.79%2.24%

Arrowhead Pharmaceuticals Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXSM
Axsome Therapeutics
2.2944 of 5 stars		$65.77
-0.7%		$103.22
+56.9%		-11.6%$3.11B$223.44M-14.52502Positive News
CYTK
Cytokinetics
2.2985 of 5 stars		$31.22
-1.9%		$59.87
+91.8%		-17.1%$3.06B$94.59M-5.66409
RARE
Ultragenyx Pharmaceutical
2.5867 of 5 stars		$38.46
-0.4%		$91.30
+137.4%		0.0%$3.16B$363.33M-4.291,311Analyst Downgrade
Positive News
OGN
Organon & Co.
2.7851 of 5 stars		$11.30
-1.1%		$23.33
+106.6%		-57.0%$2.89B$6.17B4.9310,000Short Interest ↑
PBH
Prestige Consumer Healthcare
2.1113 of 5 stars		$57.13
-1.6%		$97.00
+69.8%		-8.3%$2.83B$1.13B-34.42560Analyst Upgrade
Analyst Revision
HCM
HUTCHMED
1.8876 of 5 stars		$19.36
+1.4%		$29.70
+53.4%		+37.5%$3.37B$426.41M0.002,025Short Interest ↓
News Coverage
Gap Down
INSM
Insmed
2.5243 of 5 stars		$23.80
-0.6%		$41.27
+73.4%		+30.2%$3.40B$245.36M-4.52373Short Interest ↓
ZLAB
Zai Lab
2.0802 of 5 stars		$28.01
-0.4%		$79.57
+184.1%		-24.8%$2.77B$215.04M-8.982,036Analyst Report
Analyst Revision
News Coverage
EVO
Evotec
2.0848 of 5 stars		$9.78
-0.8%		$14.00
+43.1%		N/A$3.47B$791.73M0.004,952Gap Down
NUVL
Nuvalent
1.0385 of 5 stars		$62.00
-3.2%		$60.86
-1.8%		+83.7%$3.54BN/A-30.5489Insider Selling

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:ARWR) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -